call. the are joining and I'd you, for safe thank saying your colleagues the earnings by families COVID-XX Good like XXXX threat amidst I Thank morning, by you, Nate. and QX hope you pandemic. everyone, to your posed start our
reviewing results, our role, well from our the continue time minimize of aiding solution our ability the Given the focus plan in negative to virus morning spend a a and to treatments in as amount impacts of as this development the to critical business on COVID we stemming our vaccines. sizable to and QX our discussing form addition collective XX, impact to playing
the new In our the and issuing for his guidance pandemic, which second we've light in XXXX for uncertainty will today, quarter, the full the issued guidance are year remarks. cover of previously surrounding withdrawn Chris
quarter strong Regarding metrics. the the P&L key across and first we during results, quarter, saw commercial growth both
few and $X.XX QX. of double-digit we which of X% declining backlog net an both highest billion related immediately years; notably, in ending cash of continued growth on of down billion, as quarter our the year-on-year; A had segments, of XX and from net respectively, XX%, with X.Xx, as growth $XXX ending $XXX.X book-to-bill contributions versus of objectives, record year, highlights authorizations cash IPO laboratory XX.X% QX any cancellation and to QX to to ending line revenue see of X.Xx balance of the X.Xx and balance over $X.X increase not $X.XX a resulting a with net of P&L unusual million, activity and XX.X% include: did XX.X% prior strong of billion adjusted representing with EBITDA from COVID-XX; clinical of leverage following progress X.Xx growth our the respectively; sheet underlying end top million, our and in
trials patient the unmet a managing focused Fundamentally, quarter pandemic. the clinical on exist While be address to needs, through we're and needs these of not gone we to pandemic. first and result pleased with this our continue away and here have results, as now
allow us we from to pandemic and we've that business, we tailwinds taken will pandemic has never experiencing in presented our and clear emerge purpose position. a actions PPD's time. yet fact, feel our to inspiring mission been to are and from at this are In more organization the they the headwinds confident have than mitigating the COVID-XX-related work strong The
like provide across I I'd earnings COVID-XX to our and priorities call, shared update During three these an PPD's priorities. related to QX
our First, Pandemic our this Officer patient main by a Officer Medical protect Chief and priority is leadership, HR and team's clinics safety. to maximize to for employee and Chief instituted We colleague and quickly employees, patient all co-chaired safety. our safety. moved quickly Committee, across measures Through we our closed at labs Phase remote to domiciling remote-capable sites I work employee and offices, organized
customers strength. has we entered continuity both been with of business Across these strength. delivering pandemic and second dual our the from priority financial of the goals position Our of for goals, maintaining a
investments have owned-site enabled for trial and of site with to us and reputation excellence coupled in Our virtual provide remote networks, our customers. solutions digital delivery trial solutions our tools long-standing monitoring continuity
hand-in-hand working our of has pipelines. never enterprise customers' for Bill customers fulfill will their to are been provide to of our the looking customers studies. and continuity their partnership ensure needs virtual And our with related details and teams Our but guidance our to solutions more digital front, power on clear. this are across further
COVID-XX than make our the continue trials. have our on such half team resources work not visits trial active related sites and clinical studies, support to investigator shifted to progress have to customer resources more been we Although our on shifting available and impacted, to of focusing site adapted as new
low all pandemic. our partner team of their confidence that and of members levels, cross-training through across adaptability customers our in turnover is the PPD The embed continues our choice to organization of our this
strength, our impact while Regarding to to maintain it colleagues. important balance minimizing PPD financial to the been sheet talented our has
family that for hours sabbatical than the while employees XXX a a was taken a program up or this and to clear balance needs to work balanced program, cost to it entirely implemented temporary voluntary mitigation we a is cost employees where more employees savings have and this needed taking We With Choice, to take delivering call on permitted offering us reduction. approach company. short-term are
we to we execute to believe have program resume when because back close this critical to clinical of we quickly mobilize plus that up. work trial work as to do our point importantly, been has us catch-up well last will get This normalcy, full resources on is plan building Most activity. positions sites something
we more still Choice including have and where a COVID-XX-related as on implemented fast control typical in program, the addition In adding work severe a paused demand and management is delayed restrictions executive resources targeted of while hiring suite such for expansion travel, cost areas areas actions, freeze salary to for of work.
build and to The on COVID-XX of proud with pandemic. we last Speaking allowed XXX with in and coupled with franchises infectious are years, to to expertise experience trials spanning to five vaccines work, a this us over of the COVID-XX-related our awards clinical segments. position in this of date, part an space, solution and has treatments, be diseases lab leadership strength our our XX regulatory vaccines the active
clinical functions dozen with several the customers We continue involved as actively capacity to anticipation and growing be our for they our COVID-XX. services, for building vaccine of trials bidding In COVID-XX. in tackle development partner proactively targeting treatment to across we demand on additional are
As how would that time fast you'll the I recall that to quickly. in global see has companies just as that of a call, health breadth and of launch. And to proactively industry address dime the engaged that at power has from not team mentioned public studies a turned depth the quickly been has crisis. this on have who our our incredible customers have the earnings all reacted domain. I we expect team the announced and did QX mobilized COVID-XX work It
that enroll on XX,XXX studies treatment of upwards are patients. Current partnered we're projected to
industry positive conduct. to life Looking the the sciences bullish aiding represents R&D for value forward, approaches investment in I about trial coming this pandemic innovative as as of PPD to fundamentally of industry. example impact we the a a society. levels crisis expect remain provides the years have real-world adoption outlook in This our to accelerated well innovative dramatic to
also collaboration which between innovative for and CROs even medicines. the experiencing are future greater We sponsors, new pharma well of bodes regulators,
we examples believe for and demonstrated engagement strong be as unique operational differentiated well increasingly post customers commitment our us to customer by continued and growth the this model positions Lastly, will continued services, pandemic. COVID-XX excellence, discussed, to important I
Their the has saying and truly to around our to patients, of like beyond while willingness virus am I'd blunt spread exercising and our above been I go for by to remarkable, close XX,XXX-plus colleagues the customers proud of the for their caution world. in the provide now Sharbaugh, quarters situation Chief our on coming as evolves. Officer, topic results. to our the to We'll Operating continue this hard I'll thankful review updates to and I'm and operating work. Bill turn how dedication it over
